Turning Crisis into Opportunity
8 Jun. 2020.
10:30am CET/ 4.30pm SGT

Find opportunities John Lockwood from Unsplash

Join Proteona at SGInnovate “Turning Crisis into Opportunity”

Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology

Dr. Andreas Schmidt, CEO of Proteona, will be speaking at the online event “Turning Crisis into Opportunity”, organized by the Embassy of Singapore in Berlin, German Entrepreneurship Asia, and SGInnovate. The event will take place on Monday, June 8, 2020 at 10:30-11:30am (CET)/4:30pm-5:30pm (SGT).

Ambassador Laurence Bay, Ambassador of Singapore to Germany, will deliver the opening remarks.

Dr. Schmidt will draw on his entrepreneurship and venture capital experience and share insights on how startups can stay on top of crisis and transform challenges into unique opportunities. He will also discuss the swift response and development of Proteona following the onset of the COVID-19 pandemic.

Dr. Schmidt will be joined two other distinguished panellists from Germany and Singapore: Claus Karthe, Co-founder & CEO of German Entrepreneurship Aisa, and Heng Soon Pang, Head of Venture Building, SGInnovate. Dr. Andreas Kleinschmidt will moderate the panel.

Germany and Singapore have recently announced that the two countries will reinforce collaboration on startups in face of COVID-19, and will continue to support German and Singaporean startups to foster innovation and entrepreneurship.

To combat COVID-19, Proteona has launched an international alliance with partners from Singapore, Europe and the US. The alliance will develop neutralizing antibodies against SARS-CoV-2, the virus behind the pandemic, in order to protect immunocompromised individuals at risk.

Join the online event to learn more about our COVID-19 business actions.

For media queries, please contact:

Dr. Andreas Schmidt

About Proteona

Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).